Mind Medicine (MindMed) Inc (MNMD)

[Maverick75]

This week was huge for the whole Psychedelic sector and I dont mean just the big green day all around. All 3 major players are making significant progress with there trials and all have enough cash on hand to go the distance to major catalysts. Even our competitors Phase 2b trial results that were released in the new England Journal of medicine was a big step for this new new industry, although they still have some issues. Imo we are still on track for the 5-7yr payoff I was hoping for when I invested in 2020. Good luck and stay the course.

[MomsSpaghetti]

AGREE!

[Jack Torrance]

Earnings are meaningless at this stage.

[MomsSpaghetti]

Cash runway to late 2025 - stay the course and keep acquiring.

[leemalone2k3]

Earnings premarket tomorrow.
Holding jan23 2.50puts at .46. I expect more downside over the next few months.

[I-Man]

UNLESS, they go the way of ARYC with the Federal Investigations thing now...

This Admin's DOJ is hellbent going after any and all Rx/Pharma/outside of the bigboy establishment corporations...

[MomsSpaghetti]

October 2022 Investor Deck

https://mindmed.co/wp-content/uploads/2022/10/MindMed_InvestorPresentation_Oct12.22_FINAL.pdf

[BubbaInSC]

Good Publicity Sanja Gupta Explains "Psychedelic Renaissance" In America

any good publicity at this time is a good thing

https://www.cnn.com/videos/health/2022/11/03/psychedelic-magic-mushrooms-depression-study-gupta-cnntm-contd-vpx.cnn

A single dose of a synthetic version of the mind-altering component of magic mushrooms, psilocybin, improved depression in people with a treatment-resistant form of the disease, a new study found. CNN's Dr. Sanjay Gupta reports.

[MomsSpaghetti]

He also started the Cannabis wave back in the day... asshat or not, that TV program is pumped into millions of households. That's all that matters.

[MomsSpaghetti]

I have been here since the IPO... I have traded. Never bough the top. Fortunately. Yes the chart tells a story, but this is a good entry point again.

[I-Man]

Profit from what !!! The damn company did a reverse split, ruining many investors who trusted management and believe din this company. Same old BS here as elsewhere regarding mismanaged corporations, including OTC's...

[MomsSpaghetti]

2020 into 2021 was huge... 2022 shit correction and hopefully some took profits, but now is time to get back in. Media hype and training coming in next.

[MomsSpaghetti]

Jake is a POS... Also anyone who believes that FCM is legit - they are using a Penny Stock PR firm to peddle this crap and they are listing Nico on the Medihuasca staff... which has literally no online presence what so ever. FCM needs to go away.

“The FDA is the regulatory gold standard to ensure patient safety in clinical trials. Although it is a common practice to ‘offshore’ clinical trials, it is not acceptable to skirt known FDA required pre-clinical safety studies by going to another country,” said FCM’s Chad Boulanger.

Another way to read stuff like this is that Jake is basically suing criticizing MindMed today for things that he knows the company decided to do under the leadership of his Uncle Scott? When Scott is no longer (seemingly) liable?

It all just doesn't make sense wolf...

[BubbaInSC]

Sanja Gupta Explains "Psychedelic Renaissance" In America

https://www.cnn.com/videos/health/2022/11/03/psychedelic-magic-mushrooms-depression-study-gupta-cnntm-contd-vpx.cnn

A single dose of a synthetic version of the mind-altering component of magic mushrooms, psilocybin, improved depression in people with a treatment-resistant form of the disease, a new study found. CNN's Dr. Sanjay Gupta reports.

[Wolf-man jack]

WQLF SAYS; This is going to hurt the company and stock if this alleged acquisition is investigated by the Feds. What else would they uncover? Have Mercy WQLF Ahooooooo

Short Shareholders Said;

https://finance.yahoo.com/news/significant-mindmed-investor-demands-federal-120800633.html

[harry crumb]

After shorting this again an making wealth, we may take a long position with free money. A pop to 5 could happen with some miracle of positive news.

[MomsSpaghetti]

I know he's not as flashy as JR, but if you compare with what JR did... JR didn't setup a team he was a hype man. That was not really what we wanted. I think personally that Barrow is setting up a good team that is connected and well rounded.

The stock price does not reflect anything positive and again. Those that held through the up and down or bought at the top and are here now - yeah that hurts and I get it. I should have sold way more than I did the day this hit the NASDAQ, but I am sitting on free shares and this will be a big winner later.

I still feel this is a good entry point for new comers and holders alike. I have using the "buy the dip" or DCA dollar cost average BS... however, this is a good time to get in.

[I-Man]

I agree 100%

[Nosnibor]

Agreed. I love their science, mission and potential but I now hate the CEO as he is very weak in the area of investor sentiment / relations for starters. As a CEO you can get away with that on the OTCM however, MindMed is trading on the NASDAQ yet he is pure shite IMO.

[MomsSpaghetti]

Smart money will flow in...

[I-Man]

????v Pyro... They scared the sh!t out of investors doing that stunt they did now...

[MomsSpaghetti]

Great time to get back into this stock or acquire more... good things will come.

[Maverick75]

Good article. When I saw the latest Lucy data it was a 12 hour session with therapist in a clinical setting 4 times a year. It will have to be an expensive treatment to make it profitable. Glad were talking about payers not to mention IP and patent issues. Someone is going to put a new drug on the market to challenge ssri's. Just a matter of time.

[MomsSpaghetti]

Back to the Future: Psychedelics and a Return to the Concept of Recovery in Psychiatry

https://www.psychiatrictimes.com/view/back-to-the-future-psychedelics-and-a-return-to-the-concept-of-recovery-in-psychiatry

---

Modern psychiatry plays an under- discussed role in the observed epidemic of mental and brain health disorders. The prevailing model of psychopharmacology, and in medicine generally, suggests that a disease happens to reside inside of a person, and thus the disease should be the central focus of attention. That approach has its value, but it implies that treating the disease with better medicine is a sufficient objective. In CNS disorders, that has rarely proven to be the case.

To be sure, today's medicines are lacking.
Scientists have called the brain the "final frontier" of medical innovation. Most drugs presently in development are either reformulations of existing drugs or show only a marginal benefit over generics. SSRIs and their modern peers are as infamous for their side effects as they are for their inscrutable pathways to efficacy.

Thankfully, this decade has brought a resurgence of scientific and capital market attention to the deep, yet stimagized, body of research around psychedelic com- pounds as brain health medicines. And, while it is certainly simpler to treat the set of psychotropics that have recently excited the public imagination as if they are a single drug class, doing so papers over critical differences between them.

Dissociative anesthetics (ketamine, esketamine), empathogens (MDMA), and psychedelics (LSD, psilocybin, DMT, etc.) share qualities of rapid effects, a recent surge in attention, and most notably of acute, consciousness-altering effects. The similarities, however, end there. The contrasts between these treatments become most evident when considering the relationship between drug administration and concurrent psychotherapy. The dissociative state induced by ketamine, on one end of the spectrum, is not conducive to acute psychotherapeutic intervention. MDMA, on the other end, has not shown a sustained drug benefit without repeated sessions of psychotherapy soon after drug administrations. In contrast, classical psychedelics, with their notably experiential effects, have been shown to work independently of psychotherapy and to benefit from therapy.

Yet a clear relationship between subsequent sessions of psychotherapy and outcomes has not been fully explored. Although nearly everyone can benefit greatly from good psychotherapy, it is, to society's detriment, a scarce resource. Largely responsible is the financial pressure from government and private insurance providers whose low reimbursement rates for psychotherapy do not reflect its value.

Why does this matter?
These relationships between drug classes and psycho- therapy will have a profound impact on regulatory approval pathways and, critically, on insurers' willingness to pay. This, in turn, will determine if we continue to promote a two-tiered system of psychiatry that provides the highest quality treatments and resulting relief only to those who can pay, rather than to all who suffer.

The advancement of pharmacology is necessary but not sufficient for advancing the psychiatric paradigm. Psychedelic-assisted therapy is just the latest example of a provider model featuring unique treatment duration and labor-intensive delivery.

This model appears optimal for testing and implementing digital medicine solutions that improve patient outcomes and streamline the provider experience. Pre-treatment, digital medicine tools can facilitate patient education and engagement for the experience participants are about to undergo. During treatment, digital tools can support provider decision-making and reduce guesswork in environments where patients may struggle to describe their own experience. Post-treatment, these tools help providers to engage patients and monitor lagging biomarkers and side effects. All of these data points help to facilitate payer adoption of emerging therapeutic models.

Technology will also keep us honest about the differences between diagnosing a disease, managing symptoms, and effectively treating the patient. In a world where our best psychiatric practitioners spend their days dispensing and managing medications, psychotherapeutic support has been left by the wayside.

This context is critical to the resurgence of interest in psychedelic-assisted therapy. As a profession, we should welcome and support further research into a new generation of medicines, built on decades of clinical data from human trials. But we should pursue just as adamantly a return to a psychiatric model aimed at recovery, one which requires building the digital scaffolding for a new generation of treatment.

[I-Man]

I did as well. Seems to be going to OTC in time after what they did.

[KingOfSwing...Trading]

I vote against the RS at every opportunity but I guess I don’t own enough share to make a difference

[Nosnibor]

Interesting day so far with high volume.

[BubbaInSC]

Almost 1 month in oversold territory

all caused by RS and then authorizing more common shares resulting in dilution

very sad.

[KILLAZILLA]

Many people not willing to gamble with $ they don't have and certainly CAN'T afford to lose and/or be tied up for longer than 2-3 years for these trials to get approved. I would think a big pharma buyout would be in order within 12-18 months for no less than 1B MC though. So, that would be good return on investment for those willing to pull trigger and hold long.

[Porman]

What they are doing to this stock is almost criminal. There should be a dilution hold after an RS. just steadily falling down. I guess it's hard to break those pinky ways.

[harry crumb]

Under 3$, lmao. Mayb they’l have another RS

[Nosnibor]

I was fine giving him/her/it 45 seconds of my time if it leads to him/her/it having a positive word with itself.
Long term play indeed. I love the science and the potential however, I despise MindMed's CEO Robert Barrow plus his I.R. dept for the ATTROCIOUS JOB they are doing with respect to addressing the recent PPS action with the shareholders. Piss poor to say the least. Implore them to correct this and create shareholder value moving forward.

[MomsSpaghetti]

Don't waste your time... this is a long term play... We know this.

[Zardiw]

Looks like $MNMD has found a bottom level here....more or less........
Equivalent to .20 Pre Split...........fwiw....

Z

#DDAmanda Halloween Special: https://ddamanda.com/SignUpHalloween175.php

[harry crumb]

It’l b a dollar soon enough, then another rs! Lmao, made 6 digits shorting this pos already! $$$

[49andretired]

$2.25 just flashed my peeps...sad so sad...wait for the drop to $1.89 this week...l could be a buyer at $1.70...

[MomsSpaghetti]

That's a nice institutional buy

[Bearkat05]

Joseph D Sambeg Form SC 13G

https://sec.report/Document/0001104659-22-107184/

[49andretired]

Here comes 2.50 my peeps...sad so sad...

[Money $hot]

Jake Freeman Is A Genius



youtu.be/XKLzY3LAXxs

[49andretired]

.21 pre consolidation...lol..next stop is 2.50 = .16....blind leading the blind...sad so sad...

[Money $hot]

Barrow Debate Letter

mindmed.zone/barrow-letter

M$

[I-Man]

I thought George Economou was the most ruthless CEO bastard, especially when he stood outside the NASDAQ bldg few years ago, and was quoted as saying "US Investors are stupid people"....

[BubbaInSC]

Brutal Just Brutal

Basically a double whammy w/ reverse split.

really screwed over minority SH

MindMed Board is Trippin': Significant Investor Calls for Termination of Highly Dilutive Equity Offering and Pledges to Hold Board and Management Accountable through Activist Campaign
3:52 pm ET September 28, 2022 (PR Newswire)

Investors States Shareholder Requisition of Special Meeting to Effect Significant Change to the Board May be Necessary

Today, FCM MM HOLDINGS, LLC ("FCM") announces that it has sent a letter (the "Letter") to the Board of Directors (the "Board") of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) ("MindMed" or the "Company") informing the Board of FCM's vehement opposition to the Company's public offering announced on September 27, 2022 (the "Dilutive Offering"). In the Letter, FCM details how the Board's and management's actions, including the Dilutive Offering, have destroyed shareholder value, calls for the Board to immediately terminate the offering, and pledges to take action to hold the Board accountable.

"We are committed to taking whatever actions are necessary to protect the interest of shareholders"

"We are committed to taking whatever actions are necessary to protect the interest of shareholders, and we look forward to engaging in a zealous proxy campaign" said FCM Chief Executive Manager Jake Freeman.

The full text of the letter is available and can be downloaded at mindmed.zone/letterdilution

About FCM

FCM is managed by Jake Freeman and represents an investment of 6.1% of MindMed's shares outstanding.

FCM additionally represents other early investors in MindMed, including Scott Freeman and Chad Boulanger, who all have a strong interest in seeing the long-term success of MindMed.

For additional disclosure relating to public broadcast solicitations please see mindmed.zone/disclosure

Media ContactJake FreemanChief Executive ManagerFCM MM HOLDINGS, LLC30 N Gould St. Ste RSheridan, WY 82801Phone: [phone]Email: [e-mail]

https://c212.net/c/img/favicon.png?sn=NY87372&sd=2022-09-28

View original content:https://www.prnewswire.com/news-releases/mindmed-board-is-trippin-significant-investor-calls-for-termination-of-highly-dilutive-equity-offering-and-pledges-to-hold-board-and-management-accountable-through-activist-campaign-301636059.html

SOURCE FCM MM Holdings, LLC

https://rt.prnewswire.com/rt.gif?NewsItemId=NY87372&Transmission_Id=202209281551PR_NEWS_USPR_____NY87372&DateId=20220928

[BefallenKnight]

Breaking News - O’Leary is a Clueless F**kwad
Take it from someone who is in the industry, O’Leary oozed his way on to Shark Tank as a nobody who got lucky with a hit show and has parlayed that fame into a psuedo-successful personality. He was a relative nobody prior to Shark Tank and since has become a household name, using that recognition to release a bunch of financial nonsense including some underperforming index funds, half-assed “brands” and recommendations that carry weight for those foolish enough to think he has cared because he’s on TV.

Basically, O’Leary is a Kardashian with half the money and following but none of the hair. Although he may s*CK a mean D like a Kardasian…..

[I-Man]

MindMed Board is Trippin': Significant Investor Calls for Termination of Highly Dilutive Equity Offering and Pledges to Hold Board and Management Accountable through Activist Campaign
3:52 pm ET September 28, 2022 (PR Newswire)

Investors States Shareholder Requisition of Special Meeting to Effect Significant Change to the Board May be Necessary

Today, FCM MM HOLDINGS, LLC ("FCM") announces that it has sent a letter (the "Letter") to the Board of Directors (the "Board") of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) ("MindMed" or the "Company") informing the Board of FCM's vehement opposition to the Company's public offering announced on September 27, 2022 (the "Dilutive Offering"). In the Letter, FCM details how the Board's and management's actions, including the Dilutive Offering, have destroyed shareholder value, calls for the Board to immediately terminate the offering, and pledges to take action to hold the Board accountable.

"We are committed to taking whatever actions are necessary to protect the interest of shareholders"

"We are committed to taking whatever actions are necessary to protect the interest of shareholders, and we look forward to engaging in a zealous proxy campaign" said FCM Chief Executive Manager Jake Freeman.

The full text of the letter is available and can be downloaded at mindmed.zone/letterdilution

About FCM

FCM is managed by Jake Freeman and represents an investment of 6.1% of MindMed's shares outstanding.

FCM additionally represents other early investors in MindMed, including Scott Freeman and Chad Boulanger, who all have a strong interest in seeing the long-term success of MindMed.

For additional disclosure relating to public broadcast solicitations please see mindmed.zone/disclosure

Media ContactJake FreemanChief Executive ManagerFCM MM HOLDINGS, LLC30 N Gould St. Ste RSheridan, WY 82801Phone: [phone]Email: [e-mail]

https://c212.net/c/img/favicon.png?sn=NY87372&sd=2022-09-28

View original content:https://www.prnewswire.com/news-releases/mindmed-board-is-trippin-significant-investor-calls-for-termination-of-highly-dilutive-equity-offering-and-pledges-to-hold-board-and-management-accountable-through-activist-campaign-301636059.html

SOURCE FCM MM Holdings, LLC

https://rt.prnewswire.com/rt.gif?NewsItemId=NY87372&Transmission_Id=202209281551PR_NEWS_USPR_____NY87372&DateId=20220928

[Nosnibor]

MindMed’s “leadership” strike me as a bunch of clueless cuntz in some key areas. I still hold my shares as I believe in the space and the mission however, you can bet on the best horse but still be stuck with the worst Jockey. In a pickle. Time will tell.

[Nelson2]

So that’s why. More dilution!
Good grief. Another stock offering. But at $4.25?
Who buys?

GLTA

[GE_Jim]

It was in my watch list. I screen those and follow. Saw the drop premarket, read the reason why, and bought it.

[DarthYoda]

Maybe there is a more precise cash or mkt cap figure as I am just going off of yahoo, but either way, it's pretty close. Today's candle fell off the chart...

https://finance.yahoo.com/quote/MNMD?p=MNMD

https://schrts.co/VXRZaHvG